These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29025377)

  • 1. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging.
    Caresia Aroztegui AP; García Vicente AM; Alvarez Ruiz S; Delgado Bolton RC; Orcajo Rincon J; Garcia Garzon JR; de Arcocha Torres M; Garcia-Velloso MJ;
    Tumour Biol; 2017 Oct; 39(10):1010428317728285. PubMed ID: 29025377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
    Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
    J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of FDG PET/CT in the clinical management of breast cancer.
    Groheux D; Espié M; Giacchetti S; Hindié E
    Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.
    Lebon V; Alberini JL; Pierga JY; Diéras V; Jehanno N; Wartski M
    J Nucl Med; 2017 Feb; 58(2):252-257. PubMed ID: 27587709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
    Kitajima K; Miyoshi Y
    Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer.
    Özdemir A; Güven M; Binici S; Uygur S; Toktaş O
    Clin Transl Oncol; 2024 May; 26(5):1139-1146. PubMed ID: 37848693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.
    Groheux D; Giacchetti S; Delord M; Hindié E; Vercellino L; Cuvier C; Toubert ME; Merlet P; Hennequin C; Espié M
    J Nucl Med; 2013 Jan; 54(1):5-11. PubMed ID: 23213197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of
    de Jongh C; van der Meulen MP; Gertsen EC; Brenkman HJF; van Sandick JW; van Berge Henegouwen MI; Gisbertz SS; Luyer MDP; Nieuwenhuijzen GAP; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; de Steur WO; Hartgrink HH; Stoot JHMB; Hulsewe KWE; Spillenaar Bilgen EJ; van Det MJ; Kouwenhoven EA; Daams F; van der Peet DL; van Grieken NCT; Heisterkamp J; van Etten B; van den Berg JW; Pierie JP; Eker HH; Thijssen AY; Belt EJT; van Duijvendijk P; Wassenaar E; Wevers KP; Hol L; Wessels FJ; Haj Mohammad N; Frederix GWJ; van Hillegersberg R; Siersema PD; Vegt E; Ruurda JP;
    Ann Surg Oncol; 2024 Jun; 31(6):4005-4017. PubMed ID: 38526832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.